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Stefan BaumgartnerFor those who followed the fate of Hereditas in the last
months may have noticed that the journal terminated
its activity by the end of 2014. I am extremely happy to
announce that Hereditas is alive again and as a result of
this resurrection, I write this Editorial. I must admit
that around 8 months ago, I wrote a similar Editorial
for the last issue of Hereditas under the wings of the
previous publisher, Wiley. At that time, the letter was
written in a rather melancholic mood, as the tradition
of one of the oldest journals in the world dealing with
genetics seemed to come to an end. We should keep in
mind that Hereditas was founded in 1920 and was thus
pretty close to celebrating its 100th anniversary. For this
reason, we, the Editors, as well as the owner of Heredi-
tas, the Mendelian Society in Lund, are more than de-
lighted to have found BioMed Central as the new
partner for continuing our activities and we are looking
forward again to serving the scientific community
under the new wings of BioMed Central.The “old” Hereditas
Hereditas means almost 100 years of publishing in the
field of genetics. During almost one century, Hereditas
developed its distinct reputation through publishing
seminal papers. For example, did you know that the
first demonstration of the correct number of human
chromosomes (46) was demonstrated through a publi-
cation that appeared in Hereditas [1]? For a long time,
it was thought that the human female chromosome
number was 2n = 48 and that of males 2n = 47 [2]. It
was Albert Levan and his colleague who in 1956
corrected the number to 46 through his ingenious tech-
nique of preparing and staining metaphase chromo-
somes [1]. The story around the discovery is nicely
illuminated by Ulfur Arnason [3]. This 1956 publica-
tion had a profound impact on the development of
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standard for all cytogeneticists in the world.
The “new” Hereditas
When you compare the “old” Hereditas with the “new”
one, then you will notice a number of apparent changes:
 we now offer a wider selection of articles than
previously: Research articles (available before), Brief
reports (available before), Reviews (available before),
Commentaries (new), Letters to the Editor (new),
Software (new) and Opinions (new). Hence, authors
have a wider selection to choose from, and the likeliness
that their manuscript fits into one of these categories is
higher. There are also plans to have special issues on
topical issues: here, the readership is invited to come up
with appropriate suggestions, if they wish.
 Hereditas has appointed a second Editor-in-Chief,
Professor Yongyong Shi from Shanghai, China, with
whom I share the responsibility for the direction and
the activities of the Journal. I would like to use the
opportunity to warmly welcome Yongyong Shi on-
board of Hereditas, and I wish him ample satisfaction
for this post. Yongyong Shi has vast experience in the
genetics of complex traits including mental disorders,
tumors or metabolic diseases. Apart from his expertise,
he will become a major driving force for our expanding
activities in Asia and Australia.
 we now offer a large Editorial Board with eminent
scientists (meanwhile more than 40 colleagues).
 the layout of the homepage has been changed: it is
now more transparent than previously and all
relevant information for authors and readers is
readily available therein.
 the homepage is now embedded into the BioMed
Central platform.
Open access: benefits for authors
Publishing with Hereditas within BMC also means a pleth-
ora of benefits for authors: the most important one toe is distributed under the terms of the Creative Commons Attribution 4.0
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will be available and read by other scientists around the
world at no cost and independent of the budget of the
librarian. Open access also implies that once your manu-
script is accepted, it will be published online immediately.
Hence, your data are out, become readily visible and will
immediately be listed in PubMed.
Open access also means that you always have online
access to your own article, and signifies that authors keep
the Copyrights of their work and thus grant anyone the
right to reproduce and disseminate their article, provided
that it is cited accordingly. Finally, Open access journals
have to potential to reach a larger number of readers than
subscription-based journals. It is clear that you as the
authors will benefit from those facts mentioned above.Editorial policy
As mentioned above, Hereditas now has an expanded
Editorial Board with many excellent scientists at hand. It
is our policy that the editorial staff strive for a fast time
from submission to final decision on every manuscript
submitted to the journal. To this end, we use the
well-proven manuscript-submission platform, Editorial
Manager. The platform allows authors to upload their
manuscript in a intuitive fashion. Later during the
reviewing process, the platform allows full transparency
for authors to assess the stage of their manuscript. Your
manuscript will always be seen by at least 2 reviewers,
in some cases we seek the opinion of a third one. We
strive for constructive criticism by the reviewers such that
authors will receive clear guidance on how to improve the
manuscript to ultimately get it accepted. Furthermore,
upon receipt of the reviews, authors are given sufficient
time to revise their manuscript.
A wider range of research topics
As far as the research topics are concerned, the “new” Her-
editas now accepts a wider range of manuscripts than the
“old” one. We accept manuscripts across the full scope of
genetics and genomics, including those of plants, crops, mi-
croorganisms, animals, human diseases and model systems,
and, more recently, also manuscripts dealing with novel viral
sequences and bioinformatics. It is our goal to provide a
wide and interesting selection of articles to readers in future.
It is our intention to celebrate the centenary of Hereditas.
For this reason, we invite you to publish with Hereditas, a
journal with almost 100 years of tradition and sharing a
distinct reputation.
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